Health Conditions

What is on the horizon?

Even though RSV is an infection that affects a great portion of children population, there is only one FDA-approved medication available for halting the growth of RSV (ribavirin). Currently no treatment is available to completely eradicate or cure viral infections of any kind including RSV. However, there are many current clinical studies on medications for RSV prevention. Researchers are pursuing the possibility of an RSV vaccine.

Numax Anti-RSV Mab is an antibody against RSV, which is similar to Synagis. However, Numax is proposed to be at least ten times more effective than Synagis. Synagis is only available in injection formulation, but Numax will be available in an inhaled formulation. Furthermore, Numax will be indicated for both children and elderly, while Synagis is only indicated for children. This product is under investigation and has not been approved by the FDA.

Another study currently underway is looking at Motavizumab for the treatment of RSV. Motavizumab is a monoclonal antibody that researchers believe could potentially neutralize RSV. So far, studies in animal models have been fairly successful, and investigators have moved on to include human subjects in their research. Motavizumab is still under review and has not been approved by the FDA.

New drugs are being looked at daily for RSV, many drugs that are currently being researched are so new they are not even named yet, however, the outlook for RSV is looking up each day.